Do PC-3 cells express androgen receptor?
Background: Two sublines of the human prostate cancer cell line, PC-3, which is widely used as a model of prostate cancer progression, have been reported: PC-3(AR-) that do not express androgen receptor (AR), and PC-3AR+ that have measurable AR RNA but little protein.
Is PC-3 AR positive?
The majority of human prostate cancer cell lines, including the two “classical” cell lines DU-145 and PC-3, are reported to be androgen receptor (AR)-negative. However, other studies have provided evidence that the DU-145 and PC-3 cell lines express AR mRNA.
What are PC-3 cells?
PC3 (PC-3) is a human prostate cancer cell line used in prostate cancer research and drug development. PC3 cells are useful in investigating biochemical changes in advanced prostate cancer cells and in assessing their response to chemotherapeutic agents.
Do PC-3 cells express AR?
The PC3 and DU145 human prostate cancer cell lines are representative of the earlier type-I ADI prostate cancers. While these cells do not express AR, it is unclear whether they retained the coactivators necessary for AR-dependent tumor suppression.
What is DU145 cell line?
DU145 (DU-145) is a human prostate cancer cell line. DU145, PC3, and LNCaP are considered to be the standard prostate cancer cell lines used in therapeutic research.
What are LNCaP cells?
The LNCaP cell line is an epithelial cell line derived from a human prostate carcinoma. LNCaP cells grow as a loosely adherent layer of cells that are prone to growth in clusters. Do not plate LNCaP cells too sparsely or they will not grow well. Under the conditions described below they double every 48-60 hours.
What does DU145 stand for?
DU145 (DU-145) is a human prostate cancer cell line.
What does LNCaP stand for?
The LNCaP (Lymph Node Carcinoma of the Prostate) cell line was established from a metastatic lesion of human prostatic adenocarcinoma.
What is LNCaP cells?
LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old Caucasian male in 1977. The androgen receptor (AR) in LNCaP cells harbours a T877A mutations which enables the anti-androgen flutamide to act as an agonist.